Rhenman & Partners Asset Management’s Elevance Health ELV Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.46M	Buy	32,300 +17,300	+115%	+$5.69M	1.17%	33
2025 Q4	$5.26M	Sell	15,000 -7,500	-33%	-$2.53M	0.49%	63
2025 Q3	$7.27M	Sell	22,500 -22,150	-50%	-$6.89M	0.8%	44
2025 Q2	$17.4M	Sell	44,650 -4,300	-9%	-$1.73M	2.2%	15
2025 Q1	$21.3M	Buy	48,950 +25,800	+111%	+$10.4M	2.45%	13
2024 Q4	$8.54M	Sell	23,150 -27,350	-54%	-$11.4M	0.88%	43
2024 Q3	$26.3M	Sell	50,500 -35,300	-41%	-$18.9M	2.13%	17
2024 Q2	$46.5M	Buy	85,800 +16,300	+23%	+$8.62M	4.46%	2
2024 Q1	$36M	Buy	69,500 +56,500	+435%	+$28.1M	3.42%	5
2023 Q4	$6.13M	Sell	13,000 -25,000	-66%	-$11.6M	0.61%	54
2023 Q3	$16.5M	Sell	38,000 -18,000	-32%	-$8.16M	1.78%	23
2023 Q2	$24.9M	Hold	56,000	–	–	2.62%	11
2023 Q1	$25.7M	Buy	56,000 +11,000	+24%	+$5.23M	2.82%	6
2022 Q4	$23.1M	Buy	45,000 +5,000	+13%	+$2.54M	2.41%	10
2022 Q3	$21.9M	Sell	40,000 -17,000	-30%	-$8.13M	2.29%	10
2022 Q2	$27.5M	Buy	57,000 +10,801	+23%	+$5.34M	3.13%	6
2022 Q1	$22.7M	Sell	46,199 -51,801	-53%	-$23.7M	2.24%	11
2021 Q4	$45.8M	Sell	98,000 -22,000	-18%	-$9.26M	3.04%	5
2021 Q3	$44.7M	Buy	120,000 +25,000	+26%	+$9.5M	3.14%	3
2021 Q2	$36.3M	Hold	95,000	–	–	2.46%	5
2021 Q1	$34.1M	Buy	95,000 +15,000	+19%	+$4.82M	2.38%	10
2020 Q4	$25.7M	Sell	80,000 -10,000	-11%	-$3.07M	2.1%	12
2020 Q3	$24.2M	Buy	90,000 +25,000	+38%	+$6.73M	2.15%	14
2020 Q2	$17.1M	Hold	65,000	–	–	1.85%	16
2020 Q1	$14.8M	Buy	65,000 +3,000	+5%	+$818K	2.07%	13
2019 Q4	$18.7M	Buy	62,000 +2,000	+3%	+$550K	2.05%	10
2019 Q3	$14.4M	Sell	60,000 -30,000	-33%	-$8.22M	1.81%	20
2019 Q2	$25.4M	Buy	90,000 +16,355	+22%	+$4.47M	2.8%	8
2019 Q1	$21.1M	Sell	73,645 -5,000	-6%	-$1.45M	2.47%	10
2018 Q4	$20.7M	Buy	78,645 +8,645	+12%	+$2.38M	2.36%	10
2018 Q3	$19.2M	Sell	70,000 -6,000	-8%	-$1.56M	1.92%	18
2018 Q2	$18.1M	Buy	76,000 +15,000	+25%	+$3.47M	1.85%	23
2018 Q1	$13.4M	Buy	61,000 +30,000	+97%	+$7.05M	1.65%	26
2017 Q4	$6.97M	Sell	31,000 -24,000	-44%	-$5.11M	0.94%	43
2017 Q3	$10.4M	Buy	55,000 +28,532	+108%	+$5.43M	1.33%	26
2017 Q2	$4.98M	Sell	26,468 -11,000	-29%	-$1.98M	0.71%	54
2017 Q1	$6.2M	Sell	37,468 -20,789	-36%	-$3.31M	0.98%	42
2016 Q4	$8.38M	Buy	+58,257	New	+$7.8M	1.61%	22
2016 Q3	–	Sell	-40,000	Closed	-$5.25M	–	111
2016 Q2	$5.25M	Sell	40,000 -7,000	-15%	-$958K	0.93%	43
2016 Q1	$6.53M	Sell	47,000 -41,000	-47%	-$5.48M	1.3%	33
2015 Q4	$12.3M	Sell	88,000 -19,000	-18%	-$2.62M	1.86%	18
2015 Q3	$15M	Buy	107,000 +49,000	+84%	+$7.36M	2.39%	7
2015 Q2	$9.52M	Buy	58,000 +1,000	+2%	+$160K	1.14%	26
2015 Q1	$8.8M	Buy	57,000 +16,000	+39%	+$2.28M	1.48%	24
2014 Q4	$5.15M	Buy	41,000 +6,000	+17%	+$741K	1.49%	22
2014 Q3	$4.19M	Buy	35,000 +7,000	+25%	+$803K	1.23%	30
2014 Q2	$3.01M	Sell	28,000 -12,000	-30%	-$1.24M	0.89%	37
2014 Q1	$2.13M	Buy	40,000 +8,000	+25%	+$724K	0.64%	58
2013 Q4	$2.96M	Buy	+32,000	New	+$2.84M	1.16%	27

Other funds holding ELV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Rhenman & Partners Asset Management's ELV Position: Q1 2026 in Review

Rhenman & Partners Asset Management increased its Elevance Health (ELV) stake by 115% in Q1 2026, buying an estimated $5.69M and bringing the position to 32,300 shares worth $9.46M. The position accounts for 1.17% of the portfolio, ranked #33.

Rhenman & Partners Asset Management first reported a position in ELV in Q4 2013 and has held it in 49 quarters since. The position peaked at $46.5M in Q2 2024. 1,464 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

Rhenman & Partners Asset Management held 32,300 shares of Elevance Health worth $9.46M as of Q1 2026.
Rhenman & Partners Asset Management bought 17,300 Elevance Health shares in Q1 2026, an estimated $5.69M.
Elevance Health made up 1.17% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #33 holding.
Rhenman & Partners Asset Management first reported a position in Elevance Health in Q4 2013 and has held it in 49 quarters since.
Rhenman & Partners Asset Management's Elevance Health position peaked at $46.5M in Q2 2024.
1,464 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.